OSIR News Alert Osiris Therapeutics (OSIR) 12.92 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 3:06 AM

Osiris Therapeutics (OSIR) 12.92 $OSIR

Is Osiris Therapeutics (OSIR) Stock a Solid Choice Right Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 05, 7:34AM CST
Osiris Therapeutics is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OSIR: 12.92 (-0.04)

New medical chief at Osiris
Seeking Alpha - at Seeking Alpha - Wed Dec 03, 8:13AM CST

OSIR: 12.92 (-0.04)

Osiris Therapeutics Announces Expansion of the Leadership Team
Business Wire - Wed Dec 03, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, is pleased to announce the expansion of the management team with the appointment of Adrian Mollo as General Counsel and Dr. Jon Hopper as Chief Medical Officer, both reporting to Lode Debrabandere, Ph.D., President and Chief Executive Officer. Gregory Law also recently joined the Osiris management team as Vice President of Finance and Principal Accounting Officer, reporting to Philip Jacoby, Chief Financial Officer.
OSIR: 12.92 (-0.04)

Osiris Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Dec 01, 7:01AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 at 3:00 p.m. ET in New York City.
OSIR: 12.92 (-0.04)

Osiris Therapeutics Earnings Hindsight: Down 2.8% in Last 17 Days (OSIR)
Comtex SmarTrend(R) - Mon Nov 24, 9:24AM CST
Two weeks ago on November 7th, 2014 Osiris Therapeutics (NASDAQ:OSIR) reported earnings and analysts, on average, expected a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Since the company's report, shares of Osiris Therapeutics have fallen from $13.50 to $13.12, representing a loss of 2.8% in the past 17 days.
OSIR: 12.92 (-0.04)

Earnings Look Back: Osiris Therapeutics Is Down 3.3% Since Reporting Quarterly Results 1 Week Ago (OSIR)
Comtex SmarTrend(R) - Mon Nov 17, 3:25PM CST
When Osiris Therapeutics (NASDAQ:OSIR) reported earnings a week ago on November 7th, 2014, analysts, on average, expected the company to report a loss of $0.02 on sales of $14.8 million. Osiris Therapeutics actually reported earnings of $0.02 per share on sales of $17.2 million, beating EPS estimates by $0.04 and beating revenue estimates by $2.4 million. Shares of Osiris Therapeutics have slipped from $13.50 to $13.05, representing a loss of 3.3%, since the company reported earnings 10 days ago.
OSIR: 12.92 (-0.04)

Osiris Therapeutics to Present at the Canaccord Genuity Medical Technology and Diagnostics Forum
Business Wire - Mon Nov 17, 7:02AM CST
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedics and sports medicine, announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum on Thursday, November 20, 2014 at 9:00 a.m. ET in New York City.
OSIR: 12.92 (-0.04)

Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.78 (-0.06), BIIB: 344.49 (+2.16), OSIR: 12.92 (-0.04), AMAG: 40.04 (-0.79)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 4:35PM CST

AGTC: 20.18 (-1.09), BXE: 3.09 (-0.03), ROKA: 3.95 (+0.01), ALNY: 100.45 (+0.23), NCT: 4.96 (-0.07), SSRI: 5.29 (-0.08), ABCB: 25.21 (-0.28), OSIR: 12.92 (-0.04), XCO: 2.24 (-0.20), JDST: 19.16 (+1.17)

Osiris Therapeutics' (OSIR) CEO Lode Debrabandere on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 11:00AM CST

OSIR: 12.92 (-0.04)

Osiris ups revenues 149% in Q3
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 8:19AM CST

OSIR: 12.92 (-0.04)

Osiris Therapeutics (OSIR) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Fri Nov 07, 7:55AM CST

OSIR: 12.92 (-0.04)

Osiris Therapeutics beats by $0.03, beats on revenue
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 7:10AM CST

OSIR: 12.92 (-0.04)

Osiris posts 3Q profit
Automated Insights - Fri Nov 07, 7:09AM CST
COLUMBIA, Md. (AP) _ Osiris Therapeutics Inc. (OSIR) on Friday reported net income of $645,000 in its third quarter.
OSIR: 12.92 (-0.04)

Osiris Therapeutics Announces Third Quarter 2014 Financial Results: Revenue up 29% and Company Turned Profitable
Business Wire - Fri Nov 07, 7:00AM CST
Osiris Therapeutics, Inc. (NASDAQ: OSIR), the leading cellular and regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine, announced today its financial results for the third quarter of 2014.
OSIR: 12.92 (-0.04)

Reckitt Benckiser Pharmaceuticals Inc. Announces Appointment of Chief Financial Officer
PR Newswire - Tue Nov 04, 7:00AM CST
Reckitt Benckiser Pharmaceuticals Inc., a global specialty pharmaceutical company committed to pioneering innovative and accessible therapies for the chronic diseases of addiction and related mental health disorders, today announced the appointment of Cary J. Claiborne as Chief Financial Officer. Cary will lead the company's global financial and information technology operations, reporting to Chief Executive Officer Shaun Thaxter effective November 10, 2014.
SCMP: 13.93 (-0.13), OSIR: 12.92 (-0.04)

Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.60 (+0.01), UTHR: 129.37 (-1.86), OSIR: 12.92 (-0.04), ATHX: 1.36 (+0.05)

Osiris partners with Arthrex for the exclusive commercialisation and development of the cartilage product Cartiform
M2 - Mon Oct 20, 6:43AM CDT
Regenerative medicine company Osiris Therapeutics (NasdaqGM:OSIR) reported on Friday the launch of an exclusive commercial and development partnership for Cartiform with Arthrex, a medical device company in orthopaedics and sports medicine.
OSIR: 12.92 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

FuelCell Faces Class Action Crunch as Deadline Looms

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

ecozy's Brezzano Switch: Brewing Simplicity at Home

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

2027 Toy of the Year Finalists Energize Play Market

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...